4EGI-1 - CAS 315706-13-9
Catalog number: B0084-463344
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C18H12Cl2N4O4S
Molecular Weight:
451.28
COA:
Inquire
Targets:
Others
Description:
4EGI-1 is a competitive eIF4E/eIF4G interaction inhibitor by binding to eIF4E with KD of 25 μM.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-463344 25 mg $188 In stock
Bulk Inquiry
Purity:
>98%
Synonyms:
4EGI-1
MSDS:
Inquire
InChIKey:
KFRKRECSIYXARE-HYARGMPZSA-N
InChI:
InChI=1S/C18H12Cl2N4O4S/c19-12-6-5-10(7-13(12)20)15-9-29-18(21-15)23-22-14(17(25)26)8-11-3-1-2-4-16(11)24(27)28/h1-7,9H,8H2,(H,21,23)(H,25,26)/b22-14+
Canonical SMILES:
C1=CC=C(C(=C1)CC(=NNC2=NC(=CS2)C3=CC(=C(C=C3)Cl)Cl)C(=O)O)[N+](=O)[O-]
1.Abberant protein synthesis in G2019S LRRK2 Drosophila Parkinson disease-related phenotypes.
Martin I1, Abalde-Atristain L, Kim JW, Dawson TM, Dawson VL. Fly (Austin). 2014;8(3):165-9. doi: 10.4161/19336934.2014.983382.
LRRK2 mutations are a frequent cause of familial Parkinson disease (PD) and are also found in a number of sporadic PD cases. PD-linked G2019S and I2020T mutations in the kinase domain of LRRK2 result in elevated kinase activity, which is required for the toxicity of these pathogenic variants in cell and animal models of PD. We recently reported that LRRK2 interacts with and phosphorylates a number of mammalian ribosomal proteins, several of which exhibit increased phosphorylation via both G2019S and I2020T LRRK2. Blocking the phosphorylation of ribosomal protein s15 through expression of phospho-deficient T136A s15 prevents age-associated locomotor deficits and dopamine neuron loss caused by G2019S LRRK2 expression in Drosophila indicating that s15 is a pathogenic LRRK2 substrate. We previously described that G2019S LRRK2 causes an induction of bulk mRNA translation that is blocked by T136A s15 or the protein synthesis inhibitor anisomycin.
2.The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206.
Wang H1, Huang F, Wang J, Wang P, Lv W, Hong L, Li S, Zhou J. Cell Cycle. 2015;14(2):232-42. doi: 10.4161/15384101.2014.977096.
Cap-dependent translation is a potential cancer-related target (oncotarget) due to its critical role in cancer initiation and progression. 4EGI-1, an inhibitor of eIF4E/eIF4G interaction, was discovered by screening chemical libraries of small molecules. 4EGI-1 inhibits cap-dependent translation initiation by impairing the assembly of the eIF4E/eIF4G complex, and therefore is a potential anti-cancer agent. Here, we report that 4EGI-1 also inhibits mTORC1 signaling independent of its inhibitory role on cap-dependent translation initiation. The inhibition of mTORC1 signaling by 4EGI-1 activates Akt due to both abrogation of the negative feedback loops from mTORC1 to PI3K and activation of mTORC2. We further validated that mTORC2 activity is required for 4EGI-1-mediated Akt activation. The activated Akt counteracted the anticancer effects of 4EGI-1. In support of this model, inhibition of Akt potentiates the antitumor activity of 4EGI-1 both in vitro and in a xenograft mouse model in vivo.
3.4EGI-1 induces apoptosis and enhances radiotherapy sensitivity in nasopharyngeal carcinoma cells via DR5 induction on 4E-BP1 dephosphorylation.
Wang W1, Li J1, Wen Q1, Luo J1, Chu S1, Chen L1, Qing Z2, Xie G2, Xu L1, Alnemah MM1, Li M1, Fan S1, Zhang H1. Oncotarget. 2016 Mar 1. doi: 10.18632/oncotarget.7824. [Epub ahead of print]
The eIF4F complex regulated by a various group of eIF4E-binding proteins (4E-BPs) can initial the protein synthesis. Small molecule compound 4EGI-1, an inhibitor of the cap-dependent translation initiation through disturbing the interaction between eIF4E and eIF4G which are main elements of the eIF4E complex, has been reported to suppress cell proliferation by inducing apoptosis in many types of cancer. And death receptor 5 (DR5) is a major component in the extrinsic apoptotic pathway. However, the correlation among 4EGI-1, DR5 and 4E-BPs have not been discovered in NPC now. Therefore, we intend to find out the effect of 4EGI-1 on the apoptosis process of NPC and the relationship among 4EGI-1, DR5 and 4E-BPs. Our results revealed a significant down regulation of DR5 expression in NPC tissues, which inversely correlated with lymph node metastasis status and clinical stages. Depressed DR5 expression was an independent biomarker for poor prognosis in NPC, and elevated DR5 expression showed longer overall survival time in 174 NPC patients.
4.Cytotoxicity Induced by a Redox-silent Analog of Tocotrienol in Human Mesothelioma H2452 Cell Line via Suppression of Cap-dependent Protein Translation.
Sato A1, Ueno H2, Takase A2, Ando A3, Sekine Y4, Yano T5. Anticancer Res. 2016 Apr;36(4):1527-33.
De novo synthesis of proteins is regulated by cap-dependent protein translation. Aberrant activation of the translation is a hallmark of many cancer types including malignant mesothelioma (MM). We previously reported that a redox-silent analog of α-tocotrienol, 6-O-carboxypropyl-α-tocotrienol (T3E) induces potent cytotoxicity against human MM cells. However, the detailed mechanism of cytotoxicity of T3E remains unclear. In this study, we investigated if T3E induced potent cytotoxicity aganist MM cells. T3E reduced the formation of the cap-dependent translation complex and induced inactivation of oncogene from rat sarcoma virus (RAS). These events were associated with T3E cytotoxicity in MM cells. Furthermore, atorvastatin, an inhibitor of RAS function, had similar effects on MM cells. Moreover, 4EGI-1, a specific inhibitor of the cap-dependent translation complex, induced severe cytotoxicity in MM cells. Overall, T3E had a cytotoxic effect on MM cells via disruption of the activated cap-dependent translation complex through inactivation of RAS.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 19309-14-9 Cardamonin

Cardamonin
(CAS: 19309-14-9)

Cardamonin is a naturally occuring chalcone initially isolated from the seeds of Amomum subulatum and subsequently from other zingiberous plant species. Cardamo...

CAS 113170-86-8 Lamotrigine isethionate

Lamotrigine isethionate
(CAS: 113170-86-8)

Lamotrigine isethionate can inhibit glutamate release. It also shows anticonvulsant effects. It is an antiepileptic.

CAS 1955550-51-2 FMK 9a

FMK 9a
(CAS: 1955550-51-2)

FMK 9a is a covalent autophagin-1 inhibitor (IC50= 80 and 73 μM in FRET and LRA assay).

CAS 465-39-4 Resibufogenin

Resibufogenin
(CAS: 465-39-4)

Resibufogenin influenced peak amplitude, overshoot and half-width of the evoked single action potential, and simultaneously lessened the firing rate of evoked r...

CAS 99420-15-2 BTZO 1

BTZO 1
(CAS: 99420-15-2)

BTZO 1 is a macrophage migration inhibitory factor (MIF) binder (Kd = 68.6 nM). BTZO 1 activates antioxidant response element (ARE)-mediated gene expression and...

CAS 24280-93-1 Mycophenolic acid

Mycophenolic acid
(CAS: 24280-93-1)

Mycophenolic acid is a potent IMPDH inhibitor and the active metabolite of an immunosuppressive drug, used to prevent rejection in organ transplantation.It inhi...

CAS 1469284-79-4 PF 06424439

PF 06424439
(CAS: 1469284-79-4)

PF 06424439 is a potent, selective and orally bioavailable Diacylglycerol Acyltransferase 2 ( DGAT2) inhibitor with DGAT2 IC50 ± SEM (nM) (human/rat/dog) 14 ± 1...

NS-2214
(CAS: 171655-92-8)

NS-2214, an azabicyclo compound, has been found to be a dopamine uptake inhibitor that was once studied in the treatment of Parkinson's disease.

Chemical Structure

CAS 315706-13-9 4EGI-1

Quick Inquiry

Verification code

Featured Items